{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T03:40:55Z","timestamp":1769398855828,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T00:00:00Z","timestamp":1485043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hexal AG\/Sandoz International GmbH."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00520-017-3572-4","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T03:07:58Z","timestamp":1485054478000},"page":"1819-1828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study"],"prefix":"10.1007","volume":"25","author":[{"given":"Carsten","family":"Bokemeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Denhaerynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gorray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriy","family":"Krendyukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-4977","authenticated-orcid":false,"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,22]]},"reference":[{"key":"3572_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte- colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"3572_CR2","unstructured":"National Comprehensive Center Network (2015) 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Myeloid growth factors version 1.2015. www.nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf Accessed 8 Nov 2015"},{"key":"3572_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.critrevonc.2010.01.014","volume":"77","author":"P Gasc\u00f3n","year":"2011","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H et al (2011) Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Critical Reviews in Oncology and Hematology 77:184\u2013197","journal-title":"Critical Reviews in Oncology and Hematology"},{"key":"3572_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.critrevonc.2011.01.006","volume":"77","author":"P Gasc\u00f3n","year":"2011","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H et al (2011) Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: protocol amendments. Critical Reviews in Oncology and Hematology 77:198\u2013200","journal-title":"Critical Reviews in Oncology and Hematology"},{"key":"3572_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"P Gasc\u00f3n","year":"2016","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H et al (2016) Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer 24:911\u2013925 (Erratum published Support Care Cancer 2016;24:927)","journal-title":"Support Care Cancer"},{"key":"3572_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/annonc\/mdw309","volume":"27","author":"M Aapro","year":"2016","unstructured":"Aapro M, Ludwig H, Bokemeyer C et al (2016) Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol 27:2039\u20132045","journal-title":"Ann Oncol"},{"key":"3572_CR7","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139342834","volume-title":"Applied longitudinal data analysis for epidemiology: a practical guide","author":"JWR Twisk","year":"2013","unstructured":"Twisk JWR (2013) Applied longitudinal data analysis for epidemiology: a practical guide, 2nd edn. Cambridge University Press, Cambridge","edition":"2"},{"key":"3572_CR8","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"M Aapro","year":"2006","unstructured":"Aapro M, Cameron D, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433\u20132453","journal-title":"Eur J Cancer"},{"key":"3572_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2003","unstructured":"Crawford J, Dale D, Lyman GH (2003) Chemotherapy-induced neutropenia. Cancer 100:228\u2013237","journal-title":"Cancer"},{"key":"3572_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"N Kuderer","year":"2007","unstructured":"Kuderer N, Dale D, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"3572_CR11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","volume":"3","author":"GH Lyman","year":"2005","unstructured":"Lyman GH (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of evidence. J Natl Compr Cancer Netw 3:557\u2013571","journal-title":"J Natl Compr Cancer Netw"},{"key":"3572_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","volume":"63","author":"C Gridelli","year":"2007","unstructured":"Gridelli C, Aapro M, Barni S et al (2007) Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Critical Reviews in Oncology and Hematology 63:53\u201364","journal-title":"Critical Reviews in Oncology and Hematology"},{"key":"3572_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CCO.0b013e32832c9651","volume":"21","author":"J Klastersky","year":"2009","unstructured":"Klastersky J, Awada A, Aoun M, Paesmans M (2009) Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol 21:297\u2013302","journal-title":"Curr Opin Oncol"},{"key":"3572_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.critrevonc.2010.02.005","volume":"78","author":"J Klastersky","year":"2011","unstructured":"Klastersky J, Awada A (2011) Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Critical Reviews in Oncology and Hematology 78:17\u201323","journal-title":"Critical Reviews in Oncology and Hematology"},{"key":"3572_CR15","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484","journal-title":"Ann Oncol"},{"key":"3572_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Critical Reviews in Oncology and Hematology 90:190\u2013199","journal-title":"Critical Reviews in Oncology and Hematology"},{"key":"3572_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402\u2013407","journal-title":"Ann Pharmacother"},{"key":"3572_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/14740338.2013.770472","volume":"12","author":"I Abraham","year":"2013","unstructured":"Abraham I, Tharmarajah S, MacDonald K (2013) Clinical safety of biosimilar recombinant human granulocyte colony stimulating factors. Expert Opin Drug Saf 12:235\u2013246","journal-title":"Expert Opin Drug Saf"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3572-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:18:52Z","timestamp":1568740732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,22]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3572"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3572-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,22]]}}}